Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$2.21 +1.4%	$3.99	$1.14 ▼ $7.20	$132.37M	0.92	769,809 shs	1.16 million shs
BMEA Biomea Fusion	$1.77 +8.6%	$2.14	$1.53 ▼ $13.43	$66.50M	-0.07	909,749 shs	504,543 shs
EWTX Edgewise Therapeutics	$14.82 +1.6%	$18.01	$10.60 ▼ $38.12	$1.55B	0.36	1.16 million shs	1.40 million shs
MGNX MacroGenics	$1.59 +11.2%	$1.62	$0.99 ▼ $5.77	$100.31M	2.2	967,632 shs	433,158 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	-22.42%	+14.14%	-63.61%	-42.18%
BMEA Biomea Fusion	0.00%	-25.36%	-7.02%	-56.73%	-84.72%
EWTX Edgewise Therapeutics	0.00%	-13.78%	+27.67%	-44.65%	-20.46%
MGNX MacroGenics	0.00%	-18.29%	+10.85%	-43.70%	-56.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.2124 of 5 stars	3.5	2.0	0.0	2.4	1.7	0.6
BMEA Biomea Fusion	2.9701 of 5 stars	3.5	2.0	0.0	2.0	3.3	1.3
EWTX Edgewise Therapeutics	2.8901 of 5 stars	4.4	1.0	0.0	2.7	3.3	0.0
MGNX MacroGenics	3.9708 of 5 stars	3.2	2.0	4.4	2.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	3.00	Buy	$9.50	329.86% Upside
BMEA Biomea Fusion	3.08	Buy	$22.60	1,176.84% Upside
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$40.22	171.41% Upside
MGNX MacroGenics	2.44	Hold	$7.43	367.21% Upside

Current Analyst Ratings Breakdown

Latest ALDX, EWTX, MGNX, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/6/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
4/21/2025	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$43.00 ➝ $43.00
4/7/2025	ALDX Aldeyra Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $9.00
4/4/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/3/2025	EWTX Edgewise Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $52.00
4/2/2025	BMEA Biomea Fusion	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$11.00 ➝ $3.00
4/2/2025	EWTX Edgewise Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $51.00
4/2/2025	EWTX Edgewise Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$50.00 ➝ $14.00
3/31/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$2.04 per share	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$4.74 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.53 per share	N/A
MGNX MacroGenics	$148.34M	0.68	N/A	N/A	$2.46 per share	0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$37.54M	-$0.94	N/A	N/A	N/A	N/A	-43.01%	-33.62%	5/15/2025 (Estimated)
BMEA Biomea Fusion	-$117.25M	-$3.55	N/A	N/A	N/A	N/A	-118.90%	-93.66%	7/30/2025 (Estimated)
EWTX Edgewise Therapeutics	-$100.16M	-$1.55	N/A	N/A	N/A	N/A	-26.83%	-25.67%	N/A
MGNX MacroGenics	-$9.06M	-$1.08	N/A	N/A	N/A	-69.07%	-89.42%	-38.57%	5/13/2025 (Estimated)

Latest ALDX, EWTX, MGNX, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ALDX Aldeyra Therapeutics	-$0.25	N/A	N/A	N/A	($0.80) million	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	N/A	N/A	N/A	$9.59 million	N/A
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A
3/31/2025	Q4 2024	BMEA Biomea Fusion	-$1.00	-$0.81	+$0.19	-$0.81	N/A	N/A
3/20/2025	Q4 2024	MGNX MacroGenics	-$0.23	-$0.25	-$0.02	-$0.25	$34.17 million	$49.40 million
3/6/2025	Q4 2024	ALDX Aldeyra Therapeutics	$0.03	-$0.27	-$0.30	-$0.27	N/A	N/A
3/3/2025	Q4 2024	EWTX Edgewise Therapeutics	-$0.39	-$0.42	-$0.03	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	0.18	6.80	6.80
BMEA Biomea Fusion	N/A	3.39	3.39
EWTX Edgewise Therapeutics	N/A	26.35	26.35
MGNX MacroGenics	N/A	3.75	3.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
BMEA Biomea Fusion	96.72%
EWTX Edgewise Therapeutics	N/A
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	9.60%
BMEA Biomea Fusion	27.57%
EWTX Edgewise Therapeutics	24.11%
MGNX MacroGenics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	15	59.90 million	54.49 million	Optionable
BMEA Biomea Fusion	50	37.57 million	26.25 million	Optionable
EWTX Edgewise Therapeutics	60	104.77 million	71.86 million	Optionable
MGNX MacroGenics	430	63.09 million	55.67 million	Optionable

ALDX, EWTX, MGNX, and BMEA Headlines

Recent News About These Companies

A Look at Macrogenics's Upcoming Earnings Report

May 12 at 8:50 PM | benzinga.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from Analysts

May 12 at 6:43 AM | marketbeat.com

Price T Rowe Associates Inc. MD Decreases Holdings in MacroGenics, Inc. (NASDAQ:MGNX)

May 11 at 4:24 AM | marketbeat.com

Schonfeld Strategic Advisors LLC Makes New Investment in MacroGenics, Inc. (NASDAQ:MGNX)

May 7, 2025 | marketbeat.com

MacroGenics Announces Date of First Quarter 2025 Financial Results

May 6, 2025 | globenewswire.com

MacroGenics (MGNX) to Release Earnings on Thursday

May 3, 2025 | marketbeat.com

MacroGenics to Participate in Upcoming Investor Conference

May 1, 2025 | globenewswire.com

Renaissance Technologies LLC Raises Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)

April 29, 2025 | marketbeat.com

MacroGenics (NASDAQ:MGNX) Shares Pass Below 200 Day Moving Average - Should You Sell?

April 27, 2025 | marketbeat.com

JPMorgan Chase & Co. Acquires 221,905 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

April 27, 2025 | marketbeat.com

Wasatch Advisors LP Raises Stake in MacroGenics, Inc. (NASDAQ:MGNX)

April 19, 2025 | marketbeat.com

4 Medical Product Stocks to Buy From a Challenging Industry

April 17, 2025 | zacks.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from Brokerages

April 17, 2025 | marketbeat.com

MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

April 3, 2025 | zacks.com

Why MacroGenics, Inc.’s (MGNX) Stock Is Down 12.85%

March 27, 2025 | aaii.com

MacroGenics price target lowered to $2 from $4 at H.C. Wainwright

March 25, 2025 | markets.businessinsider.com

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

March 22, 2025 | finance.yahoo.com

Q4 2024 MacroGenics Inc Earnings Call

March 21, 2025 | uk.finance.yahoo.com

Barclays Sticks to Their Buy Rating for MacroGenics (MGNX)

March 21, 2025 | markets.businessinsider.com

MacroGenics (MGNX) Receives a Hold from Stifel Nicolaus

March 21, 2025 | markets.businessinsider.com

MacroGenics pulls plug on vobra duo ADC after seeing phase 2 prostate cancer data

March 21, 2025 | fiercebiotech.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, EWTX, MGNX, and BMEA Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$2.21 +0.03 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$2.21 0.00 (0.00%)

As of 07:54 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Biomea Fusion NASDAQ:BMEA

$1.77 +0.14 (+8.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.79 +0.02 (+1.36%)

As of 07:55 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Edgewise Therapeutics NASDAQ:EWTX

$14.82 +0.24 (+1.65%)

Closing price 04:00 PM Eastern

Extended Trading

$14.20 -0.62 (-4.21%)

As of 04:44 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

MacroGenics NASDAQ:MGNX

$1.59 +0.16 (+11.19%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.63%)

As of 07:52 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time